Assertio Holdings, Inc.

NASDAQ:ASRT

Drug Manufacturers - Specialty & Generic

Healthcare
$23.50 +0.04%

+$0.01 today

Market cap
$151.86M
Beta
0.53
P/E (TTM)
-4.2
EPS (TTM)
-$5.55
52W Low $8.61High $23.50

Volume 0.27M

Average 0.33M

ASRT EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Assertio Holdings, Inc.NASDAQ: ASRT

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$12.2M, compared with -$3.26M a year earlier. Trailing-twelve-month EBITDA was -$5.79M. Over 3 fiscal years it compounded at -67.3% a year.

Context

  • EBITDA amounted to 2.6% of revenue in FY2025, down 1.5 pp from a year earlier.
  • EBITDA increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 3 analysts of $28.45M (+806.1%) for the fiscal year ending Dec 2026, a step up from the -39.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$12.2M-137.5% QoQ
Last fiscal yearDec 2025
$3.14M-39.0% YoY
LTMMar 2026
-$5.79M-288.4% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-273.9%+218.7%+492.6 pp
1 year-39.0%+806.1%+845.1 pp
3-year CAGR-67.3%+106.5%+173.8 pp
5-year CAGR+60.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
3.14M USD
Year-over-year change
-39.0%
4-year CAGR
-46.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How ASRT compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -288.4% is the 9th highest of 10, against a peer median of +4.8%.
  • EBITDA amounts to 5.7% of revenue for ASRT, versus a peer median of 139.1%.
ASRT Competitors
EBITDA for ASRT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FBIOFortress Biotech, Inc.LTM Mar 2026$148.02M USD+264.5%—223.7%
VXRTVaxart, Inc.LTM Mar 2026$47.3M USD+203.4%—18.5%
ASRTAssertio Holdings, Inc.LTM Mar 2026-$5.79M USD-288.4%-67.3%5.7%
NTRBNutriband Inc.LTM Apr 2026-$7.89M USD+18.5%—437.7%
XBITXBiotech Inc.LTM Mar 2026-$38.33M USD-3.1%——
LUNGPulmonx CorporationLTM Mar 2026-$48.22M USD+9.4%—54.5%
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026-$78.19M USD+0.2%——
INCRInterCure Ltd.LTM Jun 2025-₪79.49M ILS-1677.7%—32.7%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026-$82.08M USD+0.7%——
TCRXTScan Therapeutics, Inc.LTM Mar 2026-$118.65M USD+4.8%—1298.7%
Peer median (excluding ASRT) —+4.8%—139.1%

Competitors are the stored peer set for ASRT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue111.01M156.23M152.07M124.96M118.71M
Cost of Revenue15.83M18.75M27.02M39.23M65.39M
Gross Profit95.18M137.49M125.05M85.73M53.33M
Gross Margin85.7%88.0%82.2%68.6%44.9%
Research & Development002.84M3.82M1.69M
Selling, General & Admin56.56M48.1M69.74M76.95M68.86M
Operating Expenses85.76M98.08M368.59M110.21M70.55M
Depreciation & Amortization29.11M33.4M28.23M25.83M30.01M
EBITDA38.78M90.17M53.17M5.15M3.14M
EBITDA Margin34.9%57.7%35.0%4.1%2.6%
Operating Income9.42M39.41M(243.54M)(24.48M)(17.22M)
Operating Margin8.5%25.2%-160.1%-19.6%-14.5%
Interest Income0003.22M2.67M
Interest Expense10.22M7.96M3.38M3.04M3.08M
Other Income / Expenses(9.98M)(8.24M)(10.52M)2.95M(12.72M)
Income Before Tax(553K)31.17M(254.05M)(21.53M)(29.94M)
Pre-Tax Margin-0.5%19.9%-167.1%-17.2%-25.2%
Income Tax Expense728K(78.46M)77.89M52K435K
Net Income(1.28M)109.63M(331.94M)(21.58M)(30.38M)
Net Margin-1.2%70.2%-218.3%-17.3%-25.6%
EPS (Basic)(0.45)34.95(70.05)(3.45)(4.74)
EPS (Diluted)(0.45)30.45(70.05)(3.45)(4.74)
Weighted Avg Shares2.88M3.13M4.74M6.35M6.4M
Weighted Avg Shares (Diluted)2.88M3.64M4.74M6.35M6.4M

Assertio Holdings, Inc.

NASDAQ:ASRT

Intrinsic Alpha fair value

Locked

Current Price

$23.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.